



UPDATE FROM THE BSRBR-RA STUDY

You can now register patients with RA starting or switching to a **number of new products** including Olumiant (baricitinib), Kevzara (sarilumab), Rixathon (rituximab), Erelzi (etanercept) and Xeljanz (tofacitinib)

Full details of relevant approvals for these new drugs can be found on our website, at <http://www.bsrbr.org/about/recruitment-announcements/>

Included in this mailing:

- Updated **eligibility table**
- Updated **checklist for registering a patient with the BSRBR-RA**
- Updated **recruitment poster** for use in clinics to make potential participants aware of the study, and if they are interested to know more or become involved then they can ask their rheumatologist or members of the clinical research teams within their hospital.
- Information on **re-registration** of patients already in the study

These documents will also be circulated electronically.

Please use baseline v11.2: 17/07/2017 for **ALL** new registrations. This can be downloaded from <http://bsrbr.org/hospitals/data-collection/>